Navigating the 'Shadow Substances': DEA's Proactive Scheduling and the Critical Imperative for Healthcare Compliance in 2025-2026

2026-07-12

The regulatory landscape for controlled substances is rapidly expanding, with the DEA increasingly targeting novel psychoactive substances (NPS) and plant-based compounds like kratom's active components. This deep dive explores the critical implications of this trend for telehealth, medspas, and other healthcare practices, detailing the risks and outlining a robust compliance framework to navigate this evolving challenge.

The ground beneath healthcare providers is constantly shifting, but few areas demand as much vigilance as the regulation of controlled substances. While the focus has historically been on traditional opioids, benzodiazepines, and stimulants, the Drug Enforcement Administration (DEA) is increasingly turning its attention to a new frontier: Novel Psychoactive Substances (NPS) and emerging plant-based compounds. These 'shadow substances,' often marketed as dietary supplements, research chemicals, or alternative therapies, pose unprecedented compliance challenges for telehealth brands, medspas, dental practices, and even traditional brick-and-mortar clinics in 2025 and 2026.

> For more on this topic, see our analysis: [The Shifting Sands of Telehealth: DEA Controlled Substance Compliance and the Rise of Novel Substance Scheduling in 2025-2026](/blog/telehealth-controlled-substance-compliance-nps).

Ignorance is not a defense in this rapidly evolving regulatory environment. The DEA's proactive scheduling, often utilizing emergency provisions, means that substances widely available today could be Schedule I tomorrow, carrying severe legal and operational ramifications. This deep dive will illuminate the DEA's strategy, the specific substances at risk, and the critical compliance measures your practice must implement to safeguard against inadvertent violations and ensure patient safety.

The DEA's Proactive Stance: Beyond Traditional Narcotics

The DEA's mandate under the Controlled Substances Act (CSA) (21 U.S.C. § 801 et seq.) is to combat drug abuse and diversion through regulation. Historically, this has involved stringent oversight of well-known pharmaceutical agents. However, the rise of designer drugs, easily modified chemical structures, and the global proliferation of unregulated plant derivatives has compelled the DEA to adopt a significantly more aggressive and proactive posture.

This shift is characterized by a growing reliance on the emergency scheduling provisions of the CSA, specifically 21 U.S.C. § 811(h). This authority allows the DEA Administrator to temporarily place a substance into Schedule I, without prior notice and comment, if it is determined that such action is necessary to avoid an 'imminent hazard to public safety.' This temporary scheduling can last for up to two years, with a potential one-year extension, providing immediate control over dangerous substances while the Department of Health and Human Services (HHS) conducts its scientific and medical evaluation.

A prime example of this trend, and one with critical implications for 2025-2026, involves substances related to 7-Hydroxymitragynine (7-OH), a primary psychoactive alkaloid found in the plant *Mitragyna speciosa* (kratom). The DEA has issued a notice of intent to temporarily place three 7-hydroxymitragynine-related substances—mitragynine pseudoindoxyl, MGM-15, and MGM-16—into Schedule I of the CSA. Concurrently, HHS is actively seeking public input on specific thresholds for 7-OH itself, signaling its potential future federal classification as a Schedule I substance above a defined concentration. These actions underscore a clear regulatory intent: to bring these 'shadow substances' under strict federal control, impacting any practice whose patients might be using them or any products that contain them.

Understanding Schedule I: The Highest Hurdle

For any healthcare practice, understanding the classification of controlled substances is foundational. Schedule I represents the highest level of federal control, reserved for substances determined to have:

A high potential for abuse.
No currently accepted medical use in treatment in the United States.
A lack of accepted safety for use of the drug or other substance under medical supervision.

This classification is not merely a formality; it carries profound implications:

Absolute Prohibition: Schedule I substances cannot be prescribed, dispensed, manufactured, or distributed legally for medical purposes. Any handling of these substances, including mere possession, is subject to severe administrative, civil, and criminal sanctions.
Research Limitations: Even for legitimate research, specialized DEA registration, highly secure storage, and rigorous record-keeping protocols are required, far beyond the scope of typical clinical practice.
Zero Tolerance: Unlike Schedule II-V substances, which permit medical use under strict guidelines, Schedule I offers no such allowances. The legal and ethical bright line is unambiguous.

The critical takeaway for healthcare providers is that once a substance, whether a traditional narcotic or a newly scheduled compound, is placed in Schedule I, all medical use and related activities cease to be legal. This necessitates an immediate and comprehensive review of patient care protocols, product offerings, and even patient education regarding self-medication practices.

The Regulatory Pathway to Scheduling: A Case Study with 7-OH

The DEA's process for scheduling novel substances is a multi-layered one, involving scientific review, public comment, and ultimately, regulatory action. Understanding this pathway is crucial for anticipating future compliance challenges.

1. Identification and Assessment: The DEA, often in collaboration with state and local law enforcement, public health agencies, and international partners, identifies emerging substances with abuse potential. 2. Referral to HHS: For permanent scheduling, the DEA Administrator requests a scientific and medical evaluation and scheduling recommendation from the Secretary of HHS. This evaluation is typically conducted by the Assistant Secretary for Health, often through the FDA. 3. HHS Evaluation: HHS conducts its review, considering factors such as a substance's actual or relative potential for abuse, scientific evidence of its pharmacological effect, its history and current pattern of abuse, and the scope, duration, and significance of abuse. For substances like 7-OH, this includes gathering data on its effects and potential for harm. The recent HHS request for public comments on a threshold for 7-hydroxymitragynine (7-OH) is a direct illustration of this phase. HHS is seeking data to support defined concentration levels that would constitute an 'imminent hazard to public safety,' which will directly inform its recommendation to the DEA. 4. DEA Determination: Based on HHS's scientific and medical recommendation and its own evaluation of factors like public health risk and international treaties, the DEA makes a final scheduling determination. 5. Emergency Scheduling (21 U.S.C. § 811(h)): As highlighted by the proposed temporary Schedule I placement for mitragynine pseudoindoxyl, MGM-15, and MGM-16, the DEA can bypass the full notice-and-comment rulemaking process if an 'imminent hazard' exists. This allows for swift action to protect public safety, but it also means providers have less lead time to adapt their practices.

This phased approach means that healthcare providers have a window, albeit often a narrow one, to monitor substances under review. The public comment periods, like the one closing on July 31, 2026, for 7-OH, are signals that federal action is imminent. Ignoring these signals is a significant compliance vulnerability.

Direct and Indirect Impacts on Healthcare Businesses (2025-2026)

The proactive scheduling of NPS and plant-based compounds by the DEA casts a wide net, affecting various healthcare entities, sometimes in unexpected ways.

Telehealth Brands

Telehealth providers, by their nature, often encounter a broad patient demographic across multiple states, some of whom may be using alternative therapies or self-medicating with unregulated substances. The scheduling of compounds like 7-OH will have several critical impacts:

Patient Screening: Telehealth platforms must enhance their patient intake and screening protocols to specifically inquire about the use of kratom products, other plant-based supplements, or novel compounds. Providers must be trained to recognize the symptoms of use and withdrawal for these substances.
Prescribing Restrictions: If a patient is found to be using a newly scheduled Schedule I substance, providers cannot legally prescribe or recommend it. Any previous recommendations, however informal, could be scrutinized.
Diversion Risk: Even if not directly prescribing, telehealth providers must be aware of the potential for patients to seek prescriptions for other controlled substances (e.g., benzodiazepines for anxiety) while also using illicitly obtained Schedule I compounds, increasing diversion risk.
Platform Liability: Telehealth platforms that facilitate connections to pharmacies or offer integrated wellness solutions must ensure that no products or recommended substances, even those offered by third parties, contain ingredients that are federally scheduled.

Medspas and Wellness Clinics

Medspas and wellness clinics frequently offer a range of products, supplements, and alternative therapies designed to enhance well-being. This sector faces unique challenges:

Product Vetting: A significant risk lies in the inclusion of scheduled compounds in seemingly innocuous 'natural' or 'wellness' products. Many such products are not FDA-regulated and may contain undeclared ingredients or derivatives of plants like kratom. Rigorous due diligence on all suppliers and ingredient lists is non-negotiable. Practices must demand certificates of analysis (COA) from suppliers and understand what they are selling or recommending.
Marketing Claims: Marketing materials for wellness products must be reviewed for any claims that could imply medical use or endorse substances that may fall under future Schedule I restrictions.
Patient Advice: Staff must be educated on newly scheduled substances to avoid inadvertently advising patients on the use or acquisition of illicit compounds, even if those compounds were previously considered 'natural' or harmless.
Reputational Risk: A single incident of a patient experiencing adverse effects from a product sold or recommended by a medspa, if that product contains a newly scheduled substance, could lead to severe reputational damage, regulatory scrutiny, and legal action.

Dental and Chiropractic Offices

While not typically prescribing controlled substances as frequently as other specialties, dental and chiropractic offices are not immune to the impacts of DEA scheduling:

Patient Dialogue: Patients in pain, or those seeking alternative relief, may inquire about or admit to using substances like kratom. Dental and chiropractic providers must be equipped to advise patients accurately and legally regarding newly scheduled substances, informing them of the legal risks and lack of accepted medical use.
Pre- and Post-Procedure Screening: For procedures requiring sedation or analgesia, providers must screen for all patient substance use, including newly scheduled NPS, to prevent adverse drug interactions or complications.
Referral Pathways: If a patient is using a scheduled substance, the practice needs clear protocols for referral to appropriate substance use disorder treatment or counseling, rather than attempting to manage it within the practice.

Healthcare Investors and Advisors

For investors and advisors, the shifting regulatory landscape creates new layers of due diligence:

Risk Assessment: Evaluate portfolio companies, especially those in telehealth, wellness, or direct-to-consumer health, for exposure to products or services that may inadvertently involve scheduled substances.
Compliance Program Review: Scrutinize the robustness of a company's controlled substance compliance program, including its ability to monitor DEA scheduling actions and adapt rapidly.
Valuation Impact: Non-compliance or enforcement actions related to scheduled substances can severely impact a company's valuation and long-term viability.

Actionable Compliance Framework for 2025-2026

In an environment where 'shadow substances' can transition to Schedule I overnight, a robust and dynamic compliance framework is not just good practice—it's essential for survival. Here's what your practice needs to implement:

1. Establish a Proactive Regulatory Intelligence System

Dedicated Monitoring: Assign a specific compliance officer or team member to monitor DEA and HHS announcements, particularly notices of intent to schedule, temporary scheduling orders, and requests for public input (like the HHS request for 7-OH data). Set up alerts for relevant federal registers and industry news feeds.
Industry Collaboration: Participate in professional organizations and forums where intelligence about emerging substances and regulatory trends is shared. TrueEval's insights are designed to be a cornerstone of this intelligence.

2. Implement Rigorous Product and Supplier Vetting

Ingredient Analysis: For all supplements, compounds, or products sold, recommended, or used within the practice, obtain and meticulously review full ingredient lists. This includes proprietary blends, as these often mask concerning components.
Supplier Due Diligence: Require suppliers to provide Certificates of Analysis (COAs) for all batches, explicitly confirming the absence of scheduled substances or their precursors. Understand their manufacturing processes and quality controls.
Periodic Re-evaluation: The regulatory status of ingredients can change. Establish a schedule for periodic re-evaluation of all products and supplier attestations.

3. Enhance Patient Screening and Education Protocols

Comprehensive Intake Forms: Update patient intake forms to specifically inquire about the use of *any* plant-based supplements (e.g., kratom, CBD products with obscure cannabinoids), 'wellness' products, or over-the-counter compounds marketed for pain, anxiety, or energy.
Provider Training on Emerging Substances: Educate all clinical staff, including front desk personnel who interact with patients, on newly scheduled substances, their common street names, typical uses, and the legal implications of their use or recommendation. Training should cover signs of abuse and withdrawal.
Patient Counseling: Develop clear, compliant messaging to educate patients on the risks and legal status of newly scheduled substances. Advise against self-medication with unregulated compounds and emphasize the importance of discussing all substance use with a healthcare provider.

4. Fortify Internal Policies and Procedures (P&Ps)

Rapid Response Plan: Develop a P&P for immediate action upon a DEA scheduling announcement, including steps for inventory removal, patient notification, and provider education.
Prescribing Guidelines: Ensure all prescribing guidelines are updated to reflect the evolving status of controlled substances, especially for telehealth providers who may encounter unique state-by-state variations on top of federal changes.
Record-Keeping: Maintain meticulous records of all products vetted, training conducted, and patient communications regarding scheduled substances.

5. Leverage Legal and Compliance Expertise

Expert Counsel: Partner with legal counsel specializing in healthcare and DEA compliance to interpret complex regulations and provide proactive guidance.
TrueEval Partnership: Utilize compliance infrastructure solutions like TrueEval to streamline monitoring, policy management, and training, ensuring your practice remains ahead of regulatory curves.

What This Means For Your Practice: A Proactive Stance is Non-Negotiable

The DEA's intensifying focus on novel psychoactive substances and plant-based compounds like 7-OH marks a significant inflection point in controlled substance compliance. For healthcare businesses, the era of relying solely on an awareness of traditional narcotics is over. The consequences of non-compliance—ranging from severe federal criminal charges and civil penalties to license revocation and exclusion from federal healthcare programs—are too high to risk.

This is not merely about avoiding fines; it's about protecting your patients, your providers, and the very viability of your practice. In 2025 and 2026, the practices that thrive will be those that embrace a proactive, dynamic, and intelligence-driven approach to controlled substance compliance, continuously adapting to the DEA's vigilance in the 'shadow substance' landscape. The time to build this resilient framework is now. Don't wait for a federal enforcement action to discover your vulnerabilities.